Skip to main content
Log in

Optimization of Individual and Population Designs Using Splus

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

We address the problem of design optimization for individual and population pharmacokinetic studies. We develop Splus generic functions for pharmacokinetic design optimization: IFIM, a function for individual design optimization similar to the ADAPT II software, and PFIM_OPT, a function for population design optimization which is an extension of the Splus function PFIM for population design evaluation. Both evaluate and optimise designs using the Simplex algorithm. IFIM optimizes the sampling times in continuous intervals of times; PFIM_OPT optimizes either, for a given group structure of the population design, only the sampling times taken in some given continuous intervals or, both the sampling times and the group structure, performing then statistical optimization. A combined variance error model can be supplied with the possibility to include parameters of the error model as parameters to be estimated. The performance of the optimization with the Simplex algorithm is demonstrated with two pharmacokinetic examples: by comparison of the optimized designs to those of the ADAPT II software for IFIM, and to those obtained using a grid search or the Fedorov–Wynn algorithm for PFIM_OPT. The influence of the variance error model on design optimization was investigated. For a given total number of samples, different group structures of a population design are compared, showing their influence on the population design efficiency. The functions IFIM and PFIM_OPT offer new efficient solutions for the increasingly important task of optimization of individual or population pharmacokinetic designs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. L. Aarons. Software for population pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 36:255-264 (1999).

    Google Scholar 

  2. L. Sheiner and J. Wakefield. Population modelling in drug development. Statistical Methods in Medical Research 8:183-193 (1999).

    Google Scholar 

  3. N. H. G. Holford, H. C. Kimko, J. P. R. Monteleone, and C. C. Peck. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:209-234 (2000).

    Google Scholar 

  4. Trial Simulator Version 2.1.2, Pharsight Corporation, 2000.

  5. M. K. Al-Banna, A. W. Kelman, and B. Whiting. Experimental design and efficient parameter estimation in population pharmacokinetics. J. Pharmacokinet. Biopharm. 18:347-360 (1990).

    Google Scholar 

  6. E. N. Jonsson, J. R. Wade, and M. O. Karlsson. Comparison of some practical sampling strategies for population pharmacokinetic studies. J. Pharmacokinet. Biopharm. 24:245-263 (1996).

    Google Scholar 

  7. J. Wang and L. Endrenyi. A computationally efficient approach for the design of population pharmacokinetic studies. J. Pharmacokinet. Biopharm. 20:279-294 (1992).

    Google Scholar 

  8. A. C. Atkinson and A. N. Donev. Optimum Experimental Designs. Clarendon Press: Oxford (1992).

    Google Scholar 

  9. E. Walter and L. Pronzato. Identification of Parametric Models. Springer: New York (1997).

    Google Scholar 

  10. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource: Los Angeles (1997).

    Google Scholar 

  11. S. Retout, S. Duffull, and F. Mentre. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput. Methods. Programs. Biomed. 65:141-151 (2001).

    Google Scholar 

  12. F. Mentré, A. Mallet, and D. Baccar. Optimal design in random-effects regression models. Biometrika 84:429-442 (1997).

    Google Scholar 

  13. S. Retout and F. Mentré. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. J. Biopharm. Stat. 13:209-227 (2003).

    Google Scholar 

  14. F. Mentré, C. Dubruc, and J. P. Thenot. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J. Pharmacokinet. Pharmacodyn. 28:299-319 (2001).

    Google Scholar 

  15. S. Retout, F. Mentré, and R. Bruno. Fisher information matrix for nonlinear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat. Med. 21:2623-2639 (2002).

    Google Scholar 

  16. M. Tod, F. Mentré, Y. Merlé, and A. Mallet. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J. Pharmacokinet. Biopharm. 26:689-716 (1998).

    Google Scholar 

  17. S. B. Duffull, F. Mentré, and L. Aarons. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm. Res. 18:83-89 (2001).

    Google Scholar 

  18. S. B. Duffull, S. Retout, and F. Mentré. The use of simulated annealing for finding optimal population designs. Comput. Methods. Programs. Biomed. 69:25-35 (2002).

    Google Scholar 

  19. A. C. Hooker, M. Foracchia, M. G. Dodds, and P. Vicini. An evaluation of population D-optimal designs via pharmacokinetic simulations. Ann. Biomed. Eng. 31:98-111 (2003).

    Google Scholar 

  20. D. Z. D'Argenio. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math. Biosci. 99:105-118 (1990).

    Google Scholar 

  21. Y. Merle and M. Tod. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J. Pharmacokinet. Pharmacodyn. 28:363-388 (2001).

    Google Scholar 

  22. M. Tod and J. M. Rocchisani. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. J. Pharmacokinet. Biopharm. 25:515-537 (1997).

    Google Scholar 

  23. J. A. Nelder and R. Mead. A simplex method for function minimization. Comput J. 7:308-313 (1965).

    Google Scholar 

  24. W. H. Press, S. A. Teukolsky, W. T. Vetterling, and B. P. Flannery. Numerical Recipies in C. 2nd edition. Cambridge University Press: New York (1992).

    Google Scholar 

  25. http://cceb.med.upenn.edu/heitjan/optimize/optfcn.q

  26. S. L. Beal and L. B. Sheiner. NONMEM users guides. University of California San Francisco, San Francisco: CA (1992).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Retout, S., Mentré, F. Optimization of Individual and Population Designs Using Splus. J Pharmacokinet Pharmacodyn 30, 417–443 (2003). https://doi.org/10.1023/B:JOPA.0000013000.59346.9a

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOPA.0000013000.59346.9a

Navigation